Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Elsevier
2024
|
| _version_ | 1826315275726749696 |
|---|---|
| author | Maurer, J Eugster, PJ Collins, K Vocat, C Oke, J Nicholson, B Rakauskas, A Grouzmann, E Valerio, M |
| author_facet | Maurer, J Eugster, PJ Collins, K Vocat, C Oke, J Nicholson, B Rakauskas, A Grouzmann, E Valerio, M |
| author_sort | Maurer, J |
| collection | OXFORD |
| description | Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PSA). We performed a comprehensive analysis of NPY, its precursors, and metabolite concentrations in both plasma and tissue samples from 181 patients using a highly specific liquid chromatography tandem mass spectrometry method. Compared with PSA, NPY and related peptides (NPYs) were less accurate at diagnosing significant prostate cancer. Combinations of NPYs in a stepwise approach did not improve a model that would be beneficial for patients. NPY may be beneficial for patients presenting with a PSA concentration in the gray area between 4 and 9 ng/ml, but the strength of this conclusion is limited. Thus, the use of NPYs as standalone or in combination with other variables, such as PSA, prostate volume, or age, to improve the diagnosis is not supported by our study. |
| first_indexed | 2024-12-09T03:21:23Z |
| format | Journal article |
| id | oxford-uuid:c3efa0ef-5e5e-4b7f-a5f6-8e7c2d1232a6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:21:23Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:c3efa0ef-5e5e-4b7f-a5f6-8e7c2d1232a62024-11-13T11:46:34ZNeuropeptide Y and derivates are not ready for prime time in prostate cancer early detectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c3efa0ef-5e5e-4b7f-a5f6-8e7c2d1232a6EnglishSymplectic ElementsElsevier2024Maurer, JEugster, PJCollins, KVocat, COke, JNicholson, BRakauskas, AGrouzmann, EValerio, MNeuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PSA). We performed a comprehensive analysis of NPY, its precursors, and metabolite concentrations in both plasma and tissue samples from 181 patients using a highly specific liquid chromatography tandem mass spectrometry method. Compared with PSA, NPY and related peptides (NPYs) were less accurate at diagnosing significant prostate cancer. Combinations of NPYs in a stepwise approach did not improve a model that would be beneficial for patients. NPY may be beneficial for patients presenting with a PSA concentration in the gray area between 4 and 9 ng/ml, but the strength of this conclusion is limited. Thus, the use of NPYs as standalone or in combination with other variables, such as PSA, prostate volume, or age, to improve the diagnosis is not supported by our study. |
| spellingShingle | Maurer, J Eugster, PJ Collins, K Vocat, C Oke, J Nicholson, B Rakauskas, A Grouzmann, E Valerio, M Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title | Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title_full | Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title_fullStr | Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title_full_unstemmed | Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title_short | Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection |
| title_sort | neuropeptide y and derivates are not ready for prime time in prostate cancer early detection |
| work_keys_str_mv | AT maurerj neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT eugsterpj neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT collinsk neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT vocatc neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT okej neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT nicholsonb neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT rakauskasa neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT grouzmanne neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection AT valeriom neuropeptideyandderivatesarenotreadyforprimetimeinprostatecancerearlydetection |